8. Analysis 05: Trial characteristics and outcomes: vitamin D combination vs. placebo.

Subcategory	Measure	01 IAGI/IGA	02 TSS	03 PASI	04 PAGI/PGA	05 Combined end point
01 Combination calcipotriol/betamethasone dipropionate, OD	Effect size [CI]	(SMD ‐1.21; 95% CI ‐1.50 to ‐0.91)	‐	(SMD ‐1.14; 95% CI ‐1.57 to ‐0.70)	(SMD ‐0.69; 95% CI ‐0.98 to ‐0.40)	(SMD ‐1.21; 95% CI ‐1.50 to ‐0.91)
02 Combination calcipotriol/betamethasone dipropionate, BD	Effect size [CI]	(SMD ‐1.90; 95% CI ‐2.09 to ‐1.71)	‐	(SMD ‐1.41; 95% CI ‐1.86 to ‐0.97)	‐	(SMD ‐1.90; 95% CI ‐2.09 to ‐1.71)
All treatments	Effect size [CI], N, I² statistic	(SMD ‐1.44; 95% CI ‐1.76 to ‐1.12); I² statistic: 89.4%	‐	(SMD ‐1.24; 95% CI ‐1.53 to ‐0.95); I² statistic: 87.6%	(SMD ‐0.69; 95% CI ‐0.98 to ‐0.40); I² statistic: NA	(SMD ‐1.44; 95% CI ‐1.76 to ‐1.12); I² statistic: 89.4%
‐	No. participants	2058	0	2056	235	2058
‐	Between‐patient design	5	0	5	1	5
‐	Within‐patient design	0	0	0	0	0
‐	Treatment duration	4 wks to 8 wks	‐	4 wks to 8 wks	8 wks	4 wks to 8 wks

For acronyms, see Table 1.